CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,923 enrolled
Drug / intervention
Moderna COVID-19 Vaccinebiological
Likely dose
Moderna COVID-19 Vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04811664
NCT04811664Phase 3Completed
CompareCT.gov

A Randomized Controlled Study to Assess SARS CoV-2 Infection, Viral Shedding, and Subsequent Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Mar 23, 2021·Updated Aug 2, 2023

In Brief

A Phase 3 clinical trial evaluating Moderna COVID-19 Vaccine for SARS-CoV-2 Infection. Completed, enrolled 1,923 participants across 51 sites.

Detailed Summary

The purpose of this study is to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in individuals immunized with the Moderna COVID-19 vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 Infection
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMar 23, 2021
Enrollment StartMar 24, 2021
Primary CompletionDec 30, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.3 years ago

Interventions

Moderna COVID-19 Vaccinebiological

A lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available). It is a suspension for intramuscular injection administered as a series of two doses (0.5 mL each) 1 month apart.